1
Clinical Trials associated with Neoantigen Peptide Vaccine(NCI)A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of a Neoantigen Peptide Vaccine Strategy in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy
This is a phase 1 open-label study to evaluate the safety and immunogenicity of a neoantigen peptide vaccine strategy in pancreatic cancer patients following surgical resection and adjuvant chemotherapy. The neoantigen peptide vaccines will incorporate prioritized neoantigens and personalized mesothelin epitopes and will be co-administered with poly-ICLC. The hypothesis of this study is that neoantigen peptide vaccines will be safe and capable of generating measurable neoantigen-specific CD4 and CD8 T cell responses.
100 Clinical Results associated with Neoantigen Peptide Vaccine(NCI)
100 Translational Medicine associated with Neoantigen Peptide Vaccine(NCI)
100 Patents (Medical) associated with Neoantigen Peptide Vaccine(NCI)
100 Deals associated with Neoantigen Peptide Vaccine(NCI)